Loading...
Catalent, Inc.
CTLT•NYSE
HealthcareDrug Manufacturers - Specialty & Generic
$63.48
$0.00(0.00%)
Catalent, Inc. (CTLT) Financial Performance & Statements
Review Catalent, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
2.46%
↑ 2.46%
Operating Income Growth
-446.72%
↓ 446.72%
Net Income Growth
-349.57%
↓ 349.57%
Operating Cash Flow Growth
2.68%
↑ 2.68%
Operating Margin
1.27%
↑ 1.27%
Gross Margin
21.82%
↑ 21.82%
Net Profit Margin
-9.34%
↓ 9.34%
ROE
-11.44%
↓ 11.44%
ROIC
0.64%
↑ 0.64%
Catalent, Inc. (CTLT) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Catalent, Inc. stock.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $1.02B | $1.30B | $1.07B | $1.02B |
| Cost of Revenue | $842.00M | $917.00M | $845.00M | $853.00M |
| Gross Profit | $181.00M | $384.00M | $229.00M | $171.00M |
| Gross Profit Ratio | $0.18 | $0.30 | $0.21 | $0.17 |
| R&D Expenses | $0.00 | $5.00M | $4.00M | $4.00M |
| SG&A Expenses | $252.00M | $218.00M | $214.00M | $180.00M |
| Operating Expenses | $252.00M | $224.00M | $246.00M | $187.00M |
| Total Costs & Expenses | $1.09B | $1.14B | $1.09B | $1.04B |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $60.00M | $65.00M | $65.00M | $66.00M |
| Depreciation & Amortization | $113.00M | $130.00M | $126.00M | $121.00M |
| EBITDA | $56.00M | $290.00M | $105.00M | $5.00M |
| EBITDA Ratio | $0.05 | $0.22 | $0.10 | $0.10 |
| Operating Income | -$71.00M | $160.00M | -$17.00M | -$16.00M |
| Operating Income Ratio | -$0.07 | $0.12 | -$0.02 | -$0.02 |
| Other Income/Expenses (Net) | -$46.00M | -$122.00M | -$92.00M | -$100.00M |
| Income Before Tax | -$117.00M | $38.00M | -$86.00M | -$182.00M |
| Income Before Tax Ratio | -$0.11 | $0.03 | -$0.08 | -$0.18 |
| Income Tax Expense | $12.00M | $15.00M | $15.00M | $24.00M |
| Net Income | -$129.00M | $23.00M | -$101.00M | -$206.00M |
| Net Income Ratio | -$0.13 | $0.02 | -$0.09 | -$0.20 |
| EPS | -$0.71 | $0.13 | -$0.55 | -$1.13 |
| Diluted EPS | -$0.71 | $0.13 | -$0.55 | -$1.13 |
| Weighted Avg Shares Outstanding | $182.00M | $181.00M | $182.00M | $182.00M |
| Weighted Avg Shares Outstanding (Diluted) | $182.00M | $183.00M | $182.00M | $182.00M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan